Using patient data, mouse models, and comprehensive in vitro and in vivo experiments, we propose a novel monocyte/macrophage-IL-15-CD226+ B cell axis in the pathogenesis of T1D, providing a theoretical foundation for T1D immunotherapies. Here, CD226 is linked to type 1 diabetes mellitus.